Coverage dated October 22, 2026 to October 26, 2026
Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery
Headline from MedicalXpress
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
MedicalXpress's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
The results are an important advance for the treatment of melanoma, oncologists said, because patients lived significantly longer without their cancer returning.
By Meg Tirrell, CNN (CNN) — When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated.
A first-of-its-kind cancer vaccine is helping significantly reduce the chances that melanoma patients' tumors return. Drugmakers Moderna and Merck announced the results Thursday. The vaccine was custom-brewed for each patient to match their tumor.
Nature, Published online: 23 October 2026; doi:10.1038/d41586-026-03417-0 Long-awaited results from phase III trial show a huge benefit in treating treatment-resistant melanoma.
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
An assistant conducts cancer vaccine research in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. The forthcoming RSV shot, expected to get US regulatory approval this month, is Moderna’s first chance to show the versatility of mRNA technology to …
Trial results represent ‘foundational shift’ in approach to cancer, allowing scientists to harness immune system in more personalised way Get our new political email , free app or daily news podcast A personalised mRNA-based melanoma vaccine significantly reduces the risk of cancer recurrence or dea…
A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.
By Meg Tirrell, CNN (CNN) — When the news arrived in August that what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma, oncologists and the public alike were exhilarated.
Experimental personalized cancer vaccines made with mRNA and some other approaches also are being tested against other types of cancer including lung, kidney and pancreatic.
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
Related updates
Separate coverage close to this update in time and subject.
